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Abstract
Objective—To follow-up previous studies highlighting a possible role for cytochrome P450,
family 2, subfamily C, 19 (CYP2C19) in susceptibility to endometriosis by searching for
additional variants in the CYP2C19 gene that may be associated with the disease.
Design—Case-control study.
Setting—Academic research.
Subject(s)—Cases = 2,271 women with surgically confirmed endometriosis; Controls = 939
women with self-report of no endometriosis and 1,770 unscreened population samples.
Intervention(s)—Sequencing of the CYP2C19 region and follow-up of 80 SNPs in two case-
control samples.
Main outcome measure(s)—Allele frequency differences between cases and controls.
Results—Sequencing of the CYP2C19 gene region resulted in the detection of a large number of
known and novel SNPs. Genotyping of 80 polymorphic SNPs in 901 endometriosis cases and 939
controls resulted in study-wide significant association signals for SNPs in moderate or complete
LD with rs4244285, a functional SNP in exon 5 that abrogates CYP2C19 function through the
creation of an alternative splice site. Evidence of association was also detected for another
functional SNP in the CYP2C19 promoter, rs12248560, highlighted in our previous study.
Conclusion(s)—Functional variants in CYP2C19 may contribute to endometriosis susceptibility
in both familial and sporadic cases.
Keywords
Endometriosis; association; pooled sequencing; CYP2C19; rs12248560; rs4244285
Introduction
Endometriosis is a gynaecological disease that affects 6-10% of women of reproductive age
and causes a variety of symptoms including severe menstrual pain, chronic pelvic pain and
subfertility (1). The disease is inherited as a complex trait (1-3), with up to 52% of the
variation in liability accounted for by genetic factors (4). Recent genome-wide association
studies (GWAS) have revealed a number of common genetic variants associated with
susceptibility to endometriosis (5-7, 8). Both linkage and association studies take advantage
of linkage disequilibrium (LD), where the alleles of SNPs located within short distances of
each other are correlated. As has been the case in other complex diseases, the causal variants
underlying endometriosis risk may be uncommon or novel SNPs in LD with the common
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markers genotyped in the original studies. Such SNPs can be detected by sequencing of
regions surrounding association and linkage signals, and may contribute more to disease risk
in the population than the common variants originally detected (9).
We recently fine-mapped a linkage peak for endometriosis on chromosome 10 (10), finding
suggestive evidence of association to the cytochrome P450 family 2, subfamily C, 19
(CYP2C19) gene (11). The CYP2C19 protein participates in the metabolism of estrogen (12,
13) and up to 10% of clinically administered medications (14) including the anti-estrogenic
drug tamoxifen (15). The gene has a number of functional variants that influence drug
metabolism, one of which, rs12248560, we found to be associated with endometriosis risk
(11). As this common SNP (minor allele frequency = 0.21) did not fully account for the
linkage signal it is possible that additional SNPs contribute to the endometriosis
susceptibility associated with this chromosomal region. Interestingly, we also found nominal
association to a SNP independent of rs12248560, rs4244285 (LD estimate r2 = 0.04), a loss-
of-function variant in CYP2C19 exon 5 which had been previously associated with
endometriosis risk in a small candidate gene study (16), although this result was not
replicated in an even smaller sample (17).
The previously detected fine-mapping association signal extended across 252.3 kilobases
(Kb) of chromosome 10 from the 3′ end of the helicase, lymphoid-specific (HELLS) gene to
the 3′ end of CYP2C19 (11). This region includes another CYP2C gene family member,
CYP2C18. In the current study, we aimed to search for additional variants in this region that
may be contributing to endometriosis risk. We screened endometriosis cases for such risk
variants using two strategies. First, to search for variants that may have a direct effect on
gene activity we screened the 5′ and 3′ untranslated regions (UTRs), exons and intron-exon
boundaries of CYP2C18 and CYP2C19 in 20 unrelated endometriosis cases with a strong
family history of disease. Next, to broaden the search to include inter-genic and intronic
regions that may harbour variants with regulatory effects on gene activity we sequenced the
entire 252.3 Kb association region in DNA pools of 384 endometriosis cases and 384
controls. Case-control association analyses were then performed on a subset of the variants
we detected by sequencing, and provided further evidence that functional SNPs in CYP2C19
may contribute to endometriosis risk.
Material and Methods
Samples
Case samples were taken from the set of 3,908 endometriosis cases with and without a
family history of disease recruited by the QIMR Berghofer Medical Research Institute
between 1995-2002 (5). All women had completed a questionnaire and provided a blood
sample. A surgical diagnosis was confirmed by retrospective examination of medical
records; disease severity was determined using the revised American Fertility Society
classification system (18). Control samples comprised unrelated individuals originally
recruited through QIMR Berghofer for either a twin study of gynaecological health who
self-reported no endometriosis (discovery sample) (4) and the sample previously utilised for
our endometriosis GWAS (replication sample) (5) recruited through the Brisbane
Adolescent Twin Study (19, 20). Approval for this study, and to obtain medical records, for
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collection of blood for DNA extraction and all questionnaires and interview schedules, and
for the inclusion of twin individuals recruited through the Australian Twin Registry, was
obtained from the QIMR Berghofer Human Research Ethics Committee. All participants
gave written informed consent.
Familial sequencing
DNA samples from 20 unrelated women from 20 of the most ‘case-dense’ endometriosis
families included in our linkage study (10) were subjected to Sanger sequencing to search
for potentially high-risk rare sequence variants contributing to endometriosis risk. Each
family had 3 or more affected first- or second-degree relatives, with the sample chosen for
sequencing having either the more severe disease (according to rAFS stages I-IV) (18), or
the earliest age of onset if affected family members had been assigned the same stage.
Primers for the PCR amplification and sequencing of the promoter and 3′ UTR regions,
intron-exon boundaries and all exons of the CYP2C18 and CYP2C19 gene were designed
using Primer 3.0 (21) (Supplementary Table 1). PCRs were performed in 15 μl reactions
containing 1X PCR buffer, 1.5 mM MgCl2, 1 U Amplitaq Gold (all Applied Biosystems,
CA, USA), 200 μM each dNTP (Promega, Madison, WI, USA), 1 μM each of forward and
reverse primers and 50 ng of DNA. PCR cycling conditions included initial denaturation at
95°C for 5 mins; ‘touchdown’ cycling at 95°C for 30 secs, 60°C (-0.5 per cycle) for 30 secs
and 72°C for 30 secs for 20 cycles; 95°C for 30 secs, 50°C for 30 secs and 72°C for 30 secs
for 15 cycles; final extension 72°C for 10 minutes. Products were verified by electrophoresis
through 2% agarose gels, cleaned with Exonuclease I and Shrimp Alkaline Phosphotase
(Fermentas, Burlington, Ontario,Canada) and sequenced using BigDye 3.0 terminator
chemistry (Applied Biosystems).
Pooled sequencing of the HELLS-CYP2C19 region
DNA samples had previously been combined into two pools comprising 384 endometriosis
cases (case pool) and 384 unrelated gynaecological health study samples (control pool) (22).
Targeted re-sequencing and analysis of the case and control DNA pools were performed by
deCODE Scientific Services (Reykjavik, Iceland). Briefly, for each pool, DNA within the
∼252.3 kb region extending from the 3′ end of HELLS to the 3′ end of CYP2C19 (covering
chromosome 10 bases 96,361,710-96,704,010 (genome build GRCh37/hg19)) was amplified
in sections by long-range PCR (average length 8,021 bases) and sequenced on an Illumina
GAIIx platform (Illumina, San Diego, CA, USA). Short read sequences were then aligned
and sequence variants (SVs; termed as such as many loci were yet to be verified) called by
deCODE using the Illumina programs CASAVA and Elandv2. In addition, we reanalysed
the sequences using programs tailored for DNA pools: sequences were aligned using the
program Novoalign (http://www.novocraft.com/main/index.php) and SVs called using
CRISP (23).
Individual genotyping and association analyses
Genotyping of SVs detected by individual and pooled sequencing was conducted in a
‘discovery’ sample of of 958 endometriosis cases and 959 unrelated gynaecological health
study controls examined in previous genetic association studies for endometriosis conducted
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at QIMR Berghofer (24-29). This sample includes all 768 individuals (384 cases and 384
controls) included in the DNA pools described above. SVs were genotyped in multiplex
assays using the Sequenom MassARRAY Genomics Platform (Sequenom, San Diego, CA,
USA). We selected 197 SVs for individual genotyping including two SNPs detected only by
familial-case sequencing, 60 SVs called by deCODE only, 60 SVs called by QIMR only and
75 SVs called by both analyses. SVs detected by targeted sequencing were included
according to the following criteria: 1) Nominally significant (P < 0.05) allele frequency
differences between the case and control pools (83 SVs across the 3 groups), and 2)
Location in potentially functional areas (e.g. all exonic SVs in addition to SVs located in 5′
and 3′ UTRs, regions of conserved sequence or within putative transcription factor binding
sites) as determined by the program ANNOVAR (112 SVs) (30).
Genotyping quality control was performed for each multiplex separately, where SVs with
>5% missing genotypes and Hardy-Weinberg P-values <1×10-4 were excluded from further
analyses. In addition, individuals missing >5% of data, or for whom we have recent genetic
evidence of non-Caucasian ancestry detected during our GWAS analysis (5), were also
removed. Single SNP and haplotype association analyses were performed including 901 of
the 958 endometriosis cases and 939 of the 959 gynaecological health study controls passing
all quality control metrics using PLINK (31). Study-wide significance at the discovery phase
(Padjusted <0.05) was determined by 10,000 permutations of the dataset, where case-control
status was randomly swapped to break the genotype-phenotype relationship while
preserving the LD structure between the SNPs, to generate empirical significance levels
corrected for multiple testing resulting from the large number of SNPs included in the study.
Replication
As only Australian samples were genotyped in the ‘discovery’ phase, we performed in silico
replication on Australian cases and controls only, using a sample comprising 1,370 unrelated
endometriosis cases and 1,770 unrelated Brisbane Adolescent Twin study controls drawn
from our recent GWAS for endometriosis (5). Briefly, all Australian GWAS individuals not
included as, or related to, an individual from the 958 case sample were utilised as cases or
controls for the replication sample. As the best SNPs from the discovery phase analysis were
not present on the Illumina 610K genotyping chips used to genotype the GWAS samples, we
analysed genotype data and dosage scores for SNPs previously imputed to HapMap2 (32).
All imputed SNPs had genotype concordance values of between 97.1-99.7% for 560
endometriosis cases for whom both actual and imputed genotypes were available, with
imputation quality scores >0.9 indicating these SNPs were imputed with a high degree of
accuracy.
Association analyses were performed in the replication dataset for three SNPs, rs1326837,
rs4244285 and rs12248560, as described above. Since only associations in the same
direction as in the discovery sample can be considered to be replicated, one-sided P-values
were obtained by halving the standard (two-sided) P-values (8). Unadjusted results obtained
for both the discovery and replication sets were then included in a meta-analysis performed
using METAL (8, 33), which converts P-values to Z-scores that are then weighted by the
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square-root of the sample size for each sample set, to determine the total evidence of
association for each SNP.
Results
Sequencing familial endometriosis cases
Sequencing of 20 cases from 20 unrelated case-dense endometriosis families for both the
CYP2C18 and CYP2C19 genes revealed the presence of a number of known SNPs in
addition to two novel intronic variants, one in intron 7 of CYP2C18 (chr10:96492949) and
the second in intron 7 of CYP2C19 (chr10:96602941). As both SNPs were located at least
50 bases from the respective intron-exon boundaries neither were predicted to have an effect
on gene-splicing (ESEfinder3.0: http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home). A number of affected women carried the known functional CYP2C19 SNPS
rs12248560 (CYP2C19*17, see http://www.cypalleles.ki.se/cyp2c19.htm for allele
nomenclature) in the promoter region (associated with endometriosis risk in our previous
fine-mapping study (11)), rs17878459 (p.Glu92Asp: CYP2C19*3) in exon 2, and rs4244285
(p.Pro271Pro: CYP2C19*2) in exon 5.
Sequencing DNA pools of endometriosis cases and controls
Sequencing of the 252.3 Kb between the end of the HELLS gene to the end of CYP2C19 in
our two DNA pools of 384 endometriosis cases and 384 controls resulted in adequate
sequence data (>500-fold coverage) for 96.8% and 94.0% of the region in each pool,
respectively. Average sequence coverage was 1,261-fold for the case pool and 1,372-fold for
the control pool. The largest gap of missing sequence (∼20 Kb) was in the region of
96.38-96.40 Mb for both pools (Supplementary Fig. 1).
deCODE Genetics called 3,051 SVs using their analysis pipeline, of which 2,418 (79%)
were novel (not present in SNP databases such as dbSNP, HapMap or the July 2010
(Phase2) release of the 1000 Genomes data). Most of the SVs were rare: 2,319 (76%) had
pool minor allele frequencies (MAFs) of <1% (range <0.0001-0.499; Table 1). At QIMR we
called 1,447 SVs using the CRISP program, of which 958 (66%) were novel, and 706 (49%)
had pool MAFs <1% (range <0.0001-0.497; Table 1). A total of 629 SVs were called by
both deCODE and QIMR using the two variant-calling approaches. Of these, 148 (23.5%)
were novel and 158 (25%) had pool MAFs <1% (range 0.0004-0.50).
Sequence variant polymorphism in individual genotyping
We selected 197 SVs for individual genotyping (of which 63 were known SNPs), including
2 SVs detected only by familial-case sequencing, 60 SVs called by deCODE only, 60 SVs
called by QIMR only, and 75 SVs called by both analyses. Genotyping of the 197 SVs in the
discovery sample revealed that 119 were in fact monomorphic (e.g. no alternative allele was
detected) in the 384 case and 384 control samples used to make up the DNA pools, although
two of these SVs were polymorphic in the larger sample of 901 cases and 939 controls
passing our quality control. Neither genomic location (inter-genic or intronic vs. exonic,
potentially functional or conserved areas) or MAF in the pools were reliable predictors of
whether SVs would be polymorphic or monomorphic when individually genotyped: SVs
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monomorphic in the individual genotyping had pool MAFs ranging from 0.001-0.40 in
either the case or control pools, while SVs polymorphic in individual genotyping had pool
MAFs ranging from 0.001-0.17.
SVs were instead more likely to be polymorphic if they were known SNPs (i.e. they had
previously been assigned an ‘rs’ number) and had been called by both variant-calling
programs utilised in this study. Only 17/134 (12.7%) novel SVs were polymorphic in
individual genotyping. Of the 63 known SNPs, 61 (97%) were polymorphic when
individually genotyped, although these had pool MAFs within the range of the SVs shown to
be monomorphic upon individual genotyping (0.001-0.5).
Fine-mapping across the CYP2C19 region
Following quality control, 80 SNPs were polymorphic in the discovery sample of 901
endometriosis cases and 939 controls included in the association analysis. A nominal
association signal (P ≤ 0.05) was detected for 35 SNPs, 19 of which remained significant
(Padjusted ≤ 0.05) following permutation to correct for multiple testing (Table 2;
Supplementary Table 2). Association signal was distributed across the sequenced region
(Fig. 1), with the best signal seen for rs1326837 (P = 4.6 × 10-5, OR = 1.38; Padjusted = 1.2 ×
10-3). All 19 significant SNPs were in moderate to high LD with each other, with analysis
conditioning on rs1326837 removing all signal from SNPs in high LD (r2 > 0.8) and
reducing but not eliminating the significance of SNPs in moderate LD (r2 0.5-0.8),
indicating that SNPs in both high and moderate LD with rs1326837 are contributing to the
endometriosis risk conferred by this haploptype.
The corresponding P-value for the 19-SNP haplotype was 8.19 × 10-5, and there was no
evidence of an independent effect for rs1326837. These 19 SNPs include rs4244285,
representing the subgroup of SNPs in moderate LD with rs1326837, which achieved an
unadjusted P = 9.2 × 10-4 (Padjusted = 2.5 × 10-2), and retained an unadjusted P = 2.7 × 10-2
in the conditional analyses.
The association signal for both rs1326837 and rs4244285 was replicated in the independent
dataset of 1,370 mostly non-familial endometriosis cases and 1,770 population controls,
with a one-sided P-value for rs1326837 of 3.1 × 10-3 (OR = 1.19), and rs4244285 P = 8.0 ×
10-3 (OR=1.18). Meta-analysis of the discovery and replication datasets produced a
combined P-value for rs1326837 of 1.3 × 10-6, and for rs4244285 of 9.4 × 10-5, surpassing
our threshold of total study-wide significance calculated as 6.2 × 10-4 (where P = 0.05/80
SNPs).
Evidence of association was also detected for rs12248560 (P = 6.4 × 10-3, OR = 0.80), the
functional promoter SNP highlighted in our previous fine-mapping study (Table 2;
Supplementary Table 2). LD between rs12248560 and SNPs of the rs1326837 haplotype is
low (average r2 = 0.04), hence the association signal was not affected by the conditional
analysis described above, indicating that this SNP represents an independent effect on
endometriosis risk. rs12248560 was, however, no longer significant following permutation
of the 901 case and 939 control dataset, indicating the signal for this SNP was not study-
wide significant in the discovery set (Padjusted = 0.16). However, there was evidence of
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association in the replication sample (1-sided P = 2.5 × 10-2, OR = 0.88), and meta-analysis
of the unadjusted discovery and replication data-sets produced a combined P-value for
rs12248560 of 5.8 × 10-4, indicating this SNP to be significant over the total study sample.
Discussion
We have found genetic variants in the CYP2C19 gene to be associated with susceptibility to
endometriosis amongst women with and without a family history of the disease. Previously,
we found the rs12248560 functional promoter SNP to be associated with a decreased risk of
endometriosis following our initial fine-mapping of a linkage peak on chromosome 10 (11).
While study-wide significant, the rs12248560 signal is somewhat reduced in the current
study (fine-mapping sample minor allele P=4.9×10-4, OR = 0.78 (11) versus current
discovery sample P=6.4×10-3, OR = 0.80), this appears mostly due to the smaller sample
size as only Australian cases and controls were included here. Although the effect of
rs12248560 on gene transcription requires clarification (CYP2C19*17 was initially
suggested to cause an ultra-rapid drug metaboliser phenotype but this has recently been
questioned (34)), this SNP has also been associated with a decreased risk of breast cancer,
particularly in women treated with hormone replacement therapy for 10 years or more (35),
indicating that functional CYP2C19 variants can influence the risk of estrogen-dependent
conditions.
The finding of additional independent association signals provides evidence for the
possibility that multiple variants contributed to the original linkage peak in this region (10).
Of particular interest is the top SNP from this study rs1326837. Located in the inter-genic
region between HELLS and CYP2C18, there is currently no evidence for a regulatory role
for this particular SNP. However, previous GWAS to find variants influencing
pharmacological drug response have detected SNPs in this inter-genic region (e.g.
rs12772169 and rs12777823) that are in complete and moderate LD with rs1326837, and are
also linked to functional SNPs in various CYP2C genes (36, 37). Such SNPs may be
contributing to the risk of endometriosis detected here.
SNPs in moderate LD with rs1326837 include the functional SNP rs4244285 (r2 = 0.64).
This synonymous SNP in CYP2C19 exon 5 causes no change to the amino acid
(p.Pro227Pro), but creates an alternative splice site 40 bases downstream resulting in a
truncated, non-functional protein (38) and a poor metaboliser phenotype (CYP2C19*2). In
our previous fine-mapping study including cases from Australia and the UK we found only
nominal association to rs4244285 (OR = 1.23, P = 1.1×10-2) in 1,158 familial and sporadic
cases (11), indicating that association with this SNP was not driving the association signal
detected in that sample. Given that the signal for rs4244285 is more significant in the current
study (discovery sample OR = 1.35, P = 9.7×10-4; meta-analysis OR = 1.35, P = 9.4×10-5)
despite the smaller sample size may indicate that the effect of this SNP on endometriosis
risk is larger in the Australian than in the UK population.
CYP2C19 participates in the conversion of 17β-estradiol (E2) to estrone (E1) (12), and in
the production of 2α-hydroxy estrogen (2α-OHE) (12, 13). This gene may exert its disease–
risk altering effects through two mechanisms, either independently or in concert. That SNPs
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causing the increased metaboliser phenotypes (rs12248560) are protective while SNPs
causing the poor metaboliser phenotype (rs4244285) increase the risk of disease supports the
hypothesis that CYP2C19 SNPs may alter endometriosis risk through an effect on local
and/or central estrogen metabolism. Altered CYP2C19 activity may affect localised, tissue-
specific rates of conversion of E2 to E1, and/or result in altered levels of the anti-estrogenic
2α-OHE metabolite, with activity either increased or decreased as compared to the wild-type
isoform depending on the true causal variant(s). Evidence for the role of other genes
involved in sex-steroid metabolism in endometriosis is currently equivocal at best, due
mostly to small sample sizes typically analysed in candidate gene studies (39, 40).
Alternatively, CYP2C19 may affect endometriosis risk through altered metabolism of
exogenous substances, which may increase the risk of developing this disease (41, 42).
CYP2C19 expression and activity is altered in response to xenobiotic as well as steroid
hormone exposure (43, 44). As seen for drug metabolism, it may be that CYP2C19 SNPs
influence the rates at which other substances metabolised by this gene are cleared, either by
the liver or locally at extra-hepatic sites, and this may moderate endometriosis risk. As the
use of plastics and associated chemicals has increased over the past decades (45), we
examined effect sizes for rs12248560 and rs4244285 by period of endometriosis diagnosis
among our cases (pre- and from 1994, the median year of diagnosis in our sample), and
while larger effects were seen for both SNPs for cases diagnosed from 1994 these results
were not significantly different (Supplementary Table 3).
In this study we sought to detect rare and possibly novel, sequence variants associated with
an increased risk of developing endometriosis through DNA sequencing of women with a
family history, and subsequent association analyses including case samples with and without
a family history of disease. Instead, the best association signals detected were for common
variants linked to known functional SNPs in the CYP2C19 gene. The effect sizes of these
CYP2C19 variants are small, but similar to variants associated with endometriosis in recent
GWAS conducted by us (5) and others (6, 7). Although our current results are not significant
at a genome-wide level, they are significant at a study-wide level and replicated in a large
independent sample. Further studies to validate our findings in additional case and control
datasets or functional experiments such as determining the association of SNPs with gene
expression in relevant tissues will help to clarify the role of CYP2C19 in estrogen-dependent
diseases. CYP2C19 is an important candidate due to its role in the metabolism of estrogen,
and possibly also other substances that might be associated with the risk of developing
endometriosis, and our study indicates that multiple SNPs in this gene region are likely to be
contributing to this risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the women who participated in the QIMR Berghofer Medical Research Institute study, and Endometriosis
Associations for supporting recruitment. The study was supported by National Health and Medical Research
Council (NHMRC) of Australia (grants 241944, 339462, 389927,389875, 389891, 389892, 389939, 443036,
Painter et al. Page 9
Fertil Steril. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
442915, 442981, 496610, 496739, 552485, 552498), the Cooperative Research Centre for Discovery of Genes for
Common Human Diseases, Cerylid Biosciences (Melbourne), and donations from Neville and Shirley Hawkins, the
Endometriosis Associations of Queensland and Western Australia, and the family of the late Kim Goodwin. The
fine-mapping data on which this study is based were generated by funding from the NIH, US, grant R01HD50537.
The GWAS data were generated as part of a study supported by the Wellcome Trust (WT084766/Z/08/Z). DRN is
supported by the NHMRC Fellowship (339462 and 613674) and ARC Future Fellowship (FT0991022) schemes,
KTZ by a Wellcome Trust Research Career Development Fellowship (WT085235/Z/08/Z) and GWM by the
NHMRC Fellowships Scheme (339446, 619667). We thank B. Haddon, D. Smyth, H. Beeby, O. Zheng, A. Henders
and additional research assistants and interviewers for database management and sample processing, and Brisbane
gynaecologist Dr Daniel T O'Connor for confirmation of diagnosis and staging of disease for some Australian
patients. We also thank the many hospital directors and staff, gynaecologists, general practitioners, and pathology
services in Australia who provided assistance with confirmation of diagnoses and blood collection, and Sullivan
Nicolaides and Queensland Medical Laboratory for pro bono collection and delivery of blood samples.
References
1. Giudice LC. Endometriosis. N Engl J Med. 2010; 362:2389–98. [PubMed: 20573927]
2. Simpson JL, Bischoff FZ. Heritability and molecular genetic studies of endometriosis. Ann N Y
Acad Sci. 2002; 955:239–51. [PubMed: 11949952]
3. Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, et al. The search for
genes contributing to endometriosis risk. Hum Reprod Update. 2008; 14:447–57. [PubMed:
18535005]
4. Treloar SA, Do KA, O'Connor VM, O'Connor DT, Yeo MA, Martin NG. Predictors of
hysterectomy: an Australian study. Am J Obstet Gynecol. 1999; 180:945–54. [PubMed: 10203663]
5. Painter JN, Anderson CA, Nyholt DR, Macgregor S, Lin JH, Lee SH, et al. Genome-wide
association study identifies a locus at 7p15.2 associated with endometriosis. Nat Genet. 2011;
43:51–4. [PubMed: 21151130]
6. Uno S, Zembutsu H, Hirasawa A, Takahashi A, Kubo M, Akahane T, et al. A genome. Nat Genet.
2012; 42:707–10. [PubMed: 20601957]
7. Adachi S, Tajima A, Quan J, Haino K, Yoshihara K, Masuzaki H, et al. Meta-analysis of genome-
wide association scans for genetic susceptibility to endometriosis in Japanese population. J Hum
Genet. 2010; 55:816–21. [PubMed: 20844546]
8. Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, et al. Genome-wide association
meta-analysis identifies new endometriosis risk loci. Nat Genet. 2012; 44:1355–9. [PubMed:
23104006]
9. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated
in antiviral responses, protect against type 1 diabetes. Science. 2009; 324:387–9. [PubMed:
19264985]
10. Treloar SA, Wicks J, Nyholt DR, Montgomery GW, Bahlo M, Smith V, et al. Genomewide linkage
study in 1,176 affected sister pair families identifies a significant susceptibility locus for
endometriosis on chromosome 10q26. Am J Hum Genet. 2005; 77:365–76. [PubMed: 16080113]
11. Painter JN, Nyholt DR, Morris A, Zhao ZZ, Henders AK, Lambert A, et al. High-density fine-
mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and
variants close to CYP2C19. Fertil Steril. 2001; 95:2236–40. [PubMed: 21497341]
12. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites
of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450
isoforms. Endocrinology. 2003; 144:3382–98. [PubMed: 12865317]
13. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM. Role of polymorphic
human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev. 2006;
15:551–8. [PubMed: 16537715]
14. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19
genetic polymorphism. Clin Pharmacokinet. 2002; 41:913–58. [PubMed: 12222994]
15. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, et al. The
CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
Pharmacogenomics. 2001; 12:1137–46. [PubMed: 21830868]
Painter et al. Page 10
Fertil Steril. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
16. Cayan F, Ayaz L, Aban M, Dilek S, Gumus LT. Role of CYP2C19 polymorphisms in patients with
endometriosis. Gynecol Endocrinol. 2009; 25:530–5. [PubMed: 19499406]
17. Bozdag G, Alp A, Saribas Z, Tuncer S, Aksu T, Gurgan T. CYP17 and CYP2C19 gene
polymorphisms in patients with endometriosis. Reprod Biomed Online. 2010:286–90. [PubMed:
20113968]
18. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985;
43:351–2. [PubMed: 3979573]
19. McGregor B, Pfitzner J, Zhu G, Grace M, Eldridge A, Pearson J, et al. Genetic and environmental
contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of
adolescent twins. Genet Epidemiol. 1999; 16:40–53. [PubMed: 9915566]
20. Zhu G, Duffy DL, Eldridge A, Grace M, Mayne C, O'Gorman L, et al. A major quantitative-trait
locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood
combined linkage and association analysis in twins and their sibs. Am J Hum Genet. 1999;
65:483–92. [PubMed: 10417291]
21. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers.
Methods Mol Biol. 2000; 132:365–86. [PubMed: 10547847]
22. Zhao ZZ, Nyholt DR, James MR, Mayne R, Treloar SA, Montgomery GW. A comparison of DNA
pools constructed following whole genome amplification for two-stage SNP genotyping designs.
Twin Res Hum Genet. 2005; 8:353–61. [PubMed: 16176720]
23. Bansal V. A statistical method for detection of variants from next-generation re-sequencing of
DNA pools. Bioinformatics. 2010; 26:i318–24. [PubMed: 20529923]
24. Treloar SA, Zhao ZZ, Le L, Zondervan KT, Martin NG, Kennedy S, et al. Variants in EMX2 and
PTEN do not contribute to risk of endometriosis. Mol Hum Reprod. 2007; 13:587–94. [PubMed:
17563403]
25. Zhao ZZ, Nyholt DR, Le L, Martin NG, James MR, Treloar SA, et al. KRAS variation and risk of
endometriosis. Mol Hum Reprod. 2006; 12:671–6. [PubMed: 16973828]
26. Zhao ZZ, Nyholt DR, Le L, Thomas S, Engwerda C, Randall L, et al. Genetic variation in tumour
necrosis factor and lymphotoxin is not associated with endometriosis in an Australian sample.
Hum Reprod. 2007; 22:2389–97. [PubMed: 17595314]
27. Zhao ZZ, Pollock PM, Thomas S, Treloar SA, Nyholt DR, Montgomery GW. Common variation
in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. Hum
Reprod. 2008; 23:1661–68. [PubMed: 18285324]
28. Zhao ZZ, Nyholt DR, Thomas S, Treloar SA, Montgomery GW. Polymorphisms in the vascular
endothelial growth factor gene and the risk of familial endometriosis. Mol Hum Reprod. 2008;
14:531–8. [PubMed: 18650217]
29. Zhao ZZ, Croft L, Nyholt DR, Chapman B, Treloar SA, Hull ML, et al. Evaluation of
polymorphisms in predicted target sites for micro RNAs differentially expressed in endometriosis.
Mol Hum Reprod. 2011; 17:92–103. [PubMed: 20935158]
30. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 2010; 38:e164. [PubMed: 20601685]
31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A tool set
for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;
81:559–75. [PubMed: 17701901]
32. Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, Zhu G, et al. Common variants in
the trichohyalin gene are associated with straight hair in Europeans. Am J Hum Genet. 2009;
85:750–5. [PubMed: 19896111]
33. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
association scans. Bioinformatics. 2010; 26:2190–1. [PubMed: 20616382]
34. Helsby NA, Burns KE. Molecular mechanisms of genetic variation and transcriptional regulation
of CYP2C19. Front Genet. 2012; 3:206. [PubMed: 23087703]
35. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al. CYP2C19*17 is
associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009; 115:391–6. [PubMed:
18521743]
Painter et al. Page 11
Fertil Steril. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
36. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of
cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel
therapy. JAMA. 2009; 302:849–57. [PubMed: 19706858]
37. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, et al. A
genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;
18:3758–68. [PubMed: 19578179]
38. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major
genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol
Chem. 1994; 269:15419–22. [PubMed: 8195181]
39. Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, et al. The search for
genes contributing to endometriosis risk. Hum Reprod Update. 2008; 14:447–57. [PubMed:
18535005]
40. Rahmioglu N, Missmer SA, Montgomery GW, Zondervan KT. Insights into assessing the genetics
of endometriosis. Curr Obstet Gynecol Rep. 2012; 1:124–37. [PubMed: 22924156]
41. Bellelis P, Podgaec S, Abrao MS. Environmental factors and endometriosis. Rev Assoc Med Bras.
2011; 57:448–52. [PubMed: 21876930]
42. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to
bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 2008; 116:39–44.
[PubMed: 18197297]
43. Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug
Metab. 2009; 10:567–78. [PubMed: 19702536]
44. Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, et al. Regulation of
CYP2C19 expression by estrogen receptor alpha: implications for estrogen-dependent inhibition of
drug metabolism. Mol Pharmacol. 2010; 78:886–94. [PubMed: 20675569]
45. Shelby MD. NTP-CERHR Monograph on the potential human reproductive and developmental
effects of bisphenol A. NTP CERHR MON. 2008:v, vii–ix, 1–64. passim. [PubMed: 19407859]
Painter et al. Page 12
Fertil Steril. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Association signal across the 252.3 Kb region between the HELLS and CYP2C19 genes on
chromosome 10. The genomic positions of the top SNP rs1326837 and the two functional
SNPs rs4244285 and rs12248560 are indicated by dashes next to the SNP names.
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Table 1
Average minor allele frequencies in the endometriosis case and control DNA pools by SNP calling method.
MAF range deCODE QIMR
< 0.001 26 (0.9%) 58 (0.04%)
0.001-0.01 2281 (74.7%) 651 (45%)
0.01-0.05 441 (14.5%) 323 (22.3%)
0.05-0.1 109 (3.5%) 152 (10.5%)
0.1-0.5 194 (6.4%) 263 (18.2%)
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